Search results
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 3 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 3 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via AOL· 3 days agoKeytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV)....
Merck halts research on combo drug for skin cancer
Becker’s Hospital Review· 3 days agoMerck will stop testing an experimental combination treatment for skin cancer patients in a late-stage study, the drugmaker said May 13. Merck was evaluating the use of the ...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 2 days agoThe drug is being studied for more than 30 types of cancer, including both monotherapy and...
Merck stops skin cancer combination therapy testing in late-stage study
WSAU Wausau· 3 days ago(Reuters) -Merck has discontinued testing a combination of an experimental antibody-based drug and...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks· 4 days agoFree Report) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab ...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via Yahoo Finance· 3 hours agoOn Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoThis year, they began studies in patients with kidney cancer, bladder cancer and a common form of...
ImmunityBio Advances On the Anktiva Front
Los Angeles Business Journal· 3 days agoImmunityBio Inc., the Culver City-based immunotherapy company founded by billionaire Patrick Soon-Shiong that last month won Food and Drug Administration approval for its ...
